Moneycontrol PRO
LAMF
LAMF
Jump to
  • Buy Ranbaxy Labs; target of Rs 800: Motilal Oswal

  • Accumulate Ranbaxy; target Rs 780: KRChoksey

  • Angel Broking neutral on Ranbaxy Laboratories

  • Accumulate Ranbaxy Labs; target of Rs 670: KRChoksey

  • Angel Broking neutral on Ranbaxy Laboratories

  • Angel Broking neutral on Ranbaxy Laboratories

  • Reduce Ranbaxy Laboratories; target Rs 417: P Lilladher

  • Hold Ranbaxy Laboratories; target Rs 308: Emkay

    Emkay Global Financial Services has recommended hold rating on Ranbaxy Laboratories with a target price of Rs 308, in its October 11, 2013 research report.

  • Hold Ranbaxy Laboratories; target Rs 308: Emkay

    Emkay Global Financial Services has recommended hold rating on Ranbaxy Laboratories with a target price of Rs 308, in its September 25, 2013 research report.

  • Angel Broking neutral on Ranbaxy Laboratories

    Angel Broking has recommended neutral rating on Ranbaxy Laboratories, in its September 17, 2013 report.

  • Angel maintains 'Neutral' rating on HDFC, Ranbaxy, GCPL

    Brokerage house Angel Broking has maintained its 'Neutral' rating on Housing Development Finance Corporation (HDFC), Ranbaxy Laboratories and Godrej Consumer Products (GCPL).

  • Angel Broking neutral on Ranbaxy Laboratories

    Angel Broking has maintained a neutral rating on Ranbaxy Laboratories (Ranbaxy) in its February 27, 2013 research report.

  • Hold Ranbaxy Laboratories; target Rs 400: Emkay

    Emkay Global Financial Services has recommended hold rating on Ranbaxy Laboratories with a target price of Rs 400, in its February 26, 2013 research report.

  • Buy Ranbaxy Labs; target of Rs 530: IIFL

    IIFL is bullish on Ranbaxy Labs and has recommended buy rating on the stock with a target of Rs 530 in its December 5, 2012 research report.

  • Accumulate Ranbaxy Labs; target of Rs 579: PLilladher

    Prabhudas Lilladher is bullish on Ranbaxy Labs and has recommended accumulate rating on the stock with a target of Rs 579 in its November 26, 2012 research report.

  • Buy Ranbaxy Labs; target of Rs 590: Emkay

    Emkay Global Financial Services is bullish on Ranbaxy Laboratories and has recommended buy rating on the stock with a target of Rs 590 in its November 8, 2012 research report.

  • Accumulate Ranbaxy; target of Rs 579: Prabhudas Lilladher

    Prabhudas Lilladher is bullish on Ranbaxy Laboratories and has recommended accumulate rating on the stock with a target of Rs 579 in its November 8, 2012 research report.

  • Buy or sell: Emkay's trading tips for Mahurat trading

    Emkay Global Financial Services has come out with its report on conviction ideas.

  • Buy Ranbaxy Labs; target of Rs 572: Nirmal Bang

    Nirmal Bang is bullish on Ranbaxy Labs and has recommended buy rating on the stock with a target of Rs 572 in its October 15 2012 research report.

  • Buy Ranbaxy Labs; target of Rs 559: Emkay

    Emkay Global Financial Services is bullish on Ranbaxy Laboratories and has recommended buy rating on the stock with a target of Rs 559 in its August 9, 2012 research report.

  • 15 stocks to buy this earning season: Emkay

    Emkay Global Financial Services has come out with its report on various stocks like Cadila Healthcare, HDFC Bank, ICICI Bank etc. The research firm recommends buying this stock.

  • GEPL Capital picks Infosys, Ranbaxy for short sell

    GEPL Capital has come out with its report on Infosys and Ranbaxy Labs.

  • Buy Ranbaxy Laboratories; target Rs 559: Emkay

    Emkay Global Financial Services is bullish on Ranbaxy Laboratories and has recommended buy rating on the stock with a target price of Rs 559 in its May 09, 2012 research report.

  • Hold Ranbaxy Laboratories; target Rs 465: Unicon Investment

    Unicon Investment has recommended hold rating on Ranbaxy Laboratories with a target price of Rs 465, in its February 24, 2012 research report.

  • Buy Ranbaxy Labs; target of Rs 504: Emkay

    Emkay Global Financial Services is bullish on Ranbaxy Labs and has recommended buy rating on the stock with a target of Rs 504 in its February 23, 2012 research report.

Advisory Alert:

It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347